LO
LOBEF.US Lobe Sciences Ltd
- Market cap
- USD 9.86M
- P/E
- -
- P/B
- 7.45x
- ROE
- -271.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to May 2026.
Is LOBEF.US undervalued?
Graham numberThe Graham number of Lobe Sciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lobe Sciences Ltd fundamental analysis
No fundamental analysis for Lobe Sciences Ltd yet.
Lobe Sciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lobe Sciences Ltd
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.
Full company profileLobe Sciences Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to May 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lobe Sciences Ltd annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 774K | 885K | 0.00 | 0.00 | 841K | 136K | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | 0.00 | 817K | 134K | 0.00 | - |
| Operating Income | -51.9K | -148K | -2.87M | -2.41M | -6.32M | -4.12M | -3.36M | -2.12M | -4.18M | -6.68M |
| EBITDA | - | - | -383K | -2.83M | - | -4.11M | -4.42M | -4.12M | -4.27M | -6.38M |
| Net Income | -51.8K | -148K | -754K | -3.44M | -9.66M | -12.3M | -4.71M | -4.42M | -4.43M | -5.11M |
| EPS | -0.01 | -0.03 | -0.01 | -0.02 | -0.04 | -0.32 | -0.06 | -0.03 | -0.02 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 30.3K | 7.44K | 6.72M | 13.0M | 12.1M | 1.75M | 2.30M | 259K | 7.59M | 5.53M |
| Total Liabilities | 6.62K | 132K | 528K | 897K | 805K | 1.30M | 2.46M | 3.37M | 2.70M | 2.33M |
| Shareholders' Equity | 23.6K | -125K | 6.19M | 12.1M | 11.3M | 446K | -160K | -3.11M | 2.36M | 1.89M |
| Cash & Short-term Investments | 29.5K | 2.66K | 513K | 172K | 1.14M | 908K | 140K | 238K | 5.85M | 1.51M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -51.9K | -2.01M | -2.04M | -1.22M | -5.04M | -2.73M | -1.72M | -462K | -1.42M | -4.46M |
| Capital Expenditure | 0.00 | 0.00 | 265K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -51.9K | -26.9K | -2.31M | -1.22M | -5.04M | -2.73M | -1.72M | -462K | -1.42M | -4.46M |
| Ratios | ||||||||||
| ROE | -219.0% | - | -12.2% | -28.5% | -85.5% | -2,749.2% | - | - | -187.9% | -271.0% |
| ROA | -171.1% | -1,993.7% | -11.2% | -26.5% | -79.8% | -701.1% | -204.7% | -1,709.7% | -58.3% | -92.4% |
| Net Profit Margin | - | - | -97.5% | -388.3% | - | - | -560.0% | -3,245.6% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lobe Sciences Ltd dividends
Lobe Sciences Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Jun 9, 2022.
Who owns Lobe Sciences Ltd
- Insiders 54.18%
- Institutions 0.00%
- Public & others 45.82%
- Shares outstanding 308M
- Free float 127M
Lobe Sciences Ltd company profile
- Company name
- Lobe Sciences Ltd
- Ticker
- LOBEF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- August
- Address
- 1771 Robson Street, Vancouver, BC, Canada, V6G 3B7
- Phone
- 949-505-5623
- Website
- lobesciences.com
About Lobe Sciences Ltd
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The company was founded in 2018 and is headquartered in Vancouver, Canada.
Lobe Sciences Ltd management
6- Dr. Frederick Dominick Sancilio M.S., Ph.D.Chairman & CEO · born 1950
- Ms. Alex SancilioVice President of Corporate Communications
- Dr. David M. Kideckel M.B.A., Ph.D.Chief Financial Officer · born 1981
- Dr. Robert Miller Ph.D.Senior Vice President of Quality and Operations
- Mr. Maghsoud Dariani B.S., M.S.Chief Science Officer · born 1954
- Dr. Tracy L. Goeken M.D.Chief Medical Officer